We hereby submit the un-audited financial results for the quarter and nine months ended December 31, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.6 pts less than Nifty Microcap 250 and 0.3 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Multibase India Limited reported unaudited results for Q3 FY26 and 9M FY26, approved by the board on February 13, 2026, with an unqualified limited review from MSKA & Associates. Q3 FY26 revenue from operations fell about 21% YoY to Rs 1,352.98 lakhs (vs Rs 1,714.78 lakhs in Q3 FY25), and 9M FY26 revenue declined roughly 11% YoY to Rs 4,881.44 lakhs (vs Rs 5,479.61 lakhs). Despite weak topline, Q3 net profit jumped about 38% YoY to Rs 328.08 lakhs (vs Rs 237.62 lakhs), aided by lower input costs and higher other income, though 9M PAT slipped about 20% YoY to Rs 844.02 lakhs. The quarter absorbed a one-time retrospective price adjustment of Rs 176.41 lakhs tied to transfer pricing on related-party imports. EPS for the quarter stood at Rs 2.60 vs Rs 1.88 in Q3 FY25.
Margin expansion cushioned Q3 profitability despite a sharp revenue drop, which is a mixed signal; investors should watch whether the revenue decline reverses, while the related-party transfer pricing adjustment is a one-off that has already been booked.